Nanoviricides Stock Price, News & Analysis

NanoViricides (NYSE American: NNVC) announced that its lead drug NV-387 showed strong activity against measles in a humanized animal model and can be made available now for emergency use via Physician Investigator Initiated INDs.

Key data: survival increased to 17 days vs 7.4 days (≈130% increase) in treated animals, dose-dependent survival, and no signs of toxicity. NV-387 completed a Phase I study in healthy subjects with no reported adverse events. The drug is manufactured under GMP in the USA and is formulated as oral gummies for easy administration.

NanoViricides (NYSE:NNVC) outlined a dual-track clinical strategy for its broad‑spectrum polymeric micelle antiviral NV-387, targeting MPox and acute respiratory viruses (influenza, coronaviruses, RSV).

Key disclosed facts: NV-387 completed a Phase 1 safety/tolerability study in 2023; an MPox Phase 2 trial has ethics approval in Congo and could begin by late CY2025–early CY2026; an adaptive respiratory “basket” Phase 2 trial in India is targeted for winter 2026 with possible US follow-ups in 2027. Management cited independent market estimates of $2.6bn for RSV and $4.6bn for influenza.

NanoViricides (NYSE:NNVC) has filed its Annual Report for fiscal year 2025, highlighting significant progress with its lead drug candidate NV-387. The broad-spectrum antiviral has advanced to Phase II clinical trials, showing promise as a potential revolutionary treatment for respiratory viral infections with a projected market size exceeding $20 billion.

The company reported cash and equivalents of $1.67 million as of June 30, 2025, with $6.83 million in net property assets. Financial challenges persist with substantial doubt about continuing operations, though the company secured a $3 million credit line and raised additional funds through ATM offerings.

Key developments include plans for Phase II MPox trials in Africa, potential US Strategic National Stockpile acquisition worth ~$1 billion for Smallpox treatment, and multiple upcoming regulatory milestones. NV-387 has demonstrated superior effectiveness compared to existing treatments in various viral infection models.

NanoViricides (NYSE American:NNVC) will present at the Life Science Executive Partnering Congress in Boston on September 17, 2025. The company's President, Dr. Anil R. Diwan, will showcase their revolutionary antiviral drug pipeline, highlighting their lead candidate NV-387.

NV-387 is an ultra-broad-spectrum antiviral designed to combat multiple respiratory viruses including RSV, Influenza A, and Coronaviruses. The drug is advancing towards Phase II trials for MPOX treatment and has shown effectiveness against multiple viruses in animal studies. The company estimates the overall market size for NV-387 indications to exceed $10 billion.

Additionally, NanoViricides has developed NV-HHV-1 for herpesvirus treatment and NV-HIV-1 for HIV treatment, both showing promising results in preclinical studies.

NanoViricides (NYSE:NNVC) will present at the LSX World Congress in Boston on September 17, 2025, where Dr. Anil R. Diwan will provide updates on the company's drug pipeline and platform technologies. The company's lead candidate, NV-387, is an ultra-broad-spectrum antiviral designed to combat multiple respiratory viruses and is advancing towards Phase II trials for MPOX treatment.

NV-387 has demonstrated effectiveness against the "tripledemic" respiratory viruses (RSV, Influenza A, Coronaviruses) and shown promise in treating Smallpox, MPox, and Measles. The drug's potential market size is estimated at over $10 billion, with additional opportunities through Priority Review Vouchers worth $150-350 million each and possible government contracts for bioterrorism defense.

NanoViricides (NYSE:NNVC) reported that its broad-spectrum antiviral drug NV-387, which has completed Phase I clinical trials, could help reduce metastatic cancer resurgence triggered by viral infections. The drug's unique ability to reduce inflammation, particularly IL-6 cytokine levels, may prevent the reactivation of dormant cancer cells during viral infections.

Research has shown that viral infections like COVID-19 and influenza can reawaken "sleeping" cancer cells, leading to metastasis. NV-387 has demonstrated superior effectiveness compared to existing treatments like Tamiflu, Rapivab, and Xofluza in protecting lungs during lethal viral infections in animal studies. The drug is being advanced to Phase II clinical trials for treating RSV, COVID, Long COVID, Influenza, and other respiratory viral infections.

NanoViricides (NYSE:NNVC) announced that its drug candidate NV-387 could be crucial in fighting the increasing global measles cases. The drug has shown effectiveness against measles in animal studies and completed Phase I trials with no adverse events. NV-387 qualifies for Orphan Drug Designation and may be eligible for Fast Track designation, potentially accelerating its approval process.

The company highlighted concerning measles statistics: 1,319 confirmed cases in the USA, 3,800 cases in Canada, and over 127,350 cases in the European Region in 2024. NV-387 addresses an unmet medical need, as there are currently no approved drugs for measles treatment, while vaccination rates struggle to maintain the required 95% coverage for herd immunity.

NanoViricides (NYSE:NNVC) has detailed the significant market potential of its broad-spectrum antiviral drug NV-387, which has shown effectiveness against multiple viruses including Influenza, Coronaviruses, RSV, MPox, and Measles. The company is advancing toward a Phase II clinical trial for MPox treatment, where NV-387 could become the first approved drug for this indication.

The drug's potential extends to pandemic preparedness, with possible effectiveness against Ebola/Marburg and Hendra/Nipah viruses. The company plans to pursue orphan drug status for several indications and may be eligible for Priority Review Vouchers worth $150-250 million each. NV-387's unique mechanism mimics HSPG, a cell-side molecule that over 90% of human pathogenic viruses bind to, making viral escape unlikely.

NanoViricides (NYSE Amer: NNVC) has achieved a significant breakthrough in developing NV-387, potentially the first-ever drug treatment for Measles. In a humanized animal model study, NV-387 demonstrated strong effectiveness, increasing survival time by 130% (17 days vs. 7.4 days in untreated animals) with no toxicity signs.

The broad-spectrum antiviral drug works by acting as a cell decoy, targeting 90-95% of human pathogenic viruses that require sulfated proteoglycan features. The study utilized specially modified mice bearing the human CD150/SLAM protein, necessary for measles infection. This development is particularly significant as global measles cases rise and vaccination rates decline, especially in industrialized nations.